MEDP vs PODD

Medpace exhibits strong operational health with a Piotroski F-Score of 7/9 and an exceptional ROE of 70.23%, reflecting a high-efficiency growth engine. However, the stock is significantly overvalued from a defensive standpoint, trading at $501.23 against a Graham Number of $74.63 and slightly above its growth-based intrinsic value of $451.35. While revenue and earnings growth remain robust, the high PEG ratio (2.98) and aggressive insider selling by the CEO and President suggest the current price may have peaked. The overall profile is that of a high-quality company trading at a premium valuation.

Insulet Corporation (PODD) presents a dichotomy between strong operational growth and a severely disconnected valuation. While the Piotroski F-Score of 4/9 indicates stable financial health and revenue growth is robust at 31.2%, the stock trades at a massive premium to its Graham Number ($41.11) and Intrinsic Value ($44.85). Despite a 'strong_buy' analyst consensus and a high target price of $333.30, the technical trend is aggressively bearish with a 36.3% decline over the last six months. The investment case relies entirely on future growth scaling and the successful international rollout of Omnipod 5 to justify the current P/E of 57.73.